Skip to main content

Cardiff Oncology, Inc.

corporate_fare Company Profile

Cardiff Oncology, Inc.

CRDF·NASDAQ·Life Sciences·CIK 0001213037

We are a clinical-stage biotechnology company focused on developing new therapies for various cancers by inhibiting PLK1, a known target in oncology. Our strategy involves combining onvansertib, our oral and highly selective PLK1 inhibitor, with standard-of-care treatments to target tumor vulnerabilities. Our clinical program primarily focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC). We also have investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Our clinical development uses tumor genomics and biomarker assays to select patients and assess their treatment response. Our lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that specifically inhibits PLK1 and has a 24-hour half-life. Onvansertib is highly potent and selective against the PLK1 enzyme (IC 50 = 2nM), unlike previous PLK1 inhibitors that targeted multiple PLK targets. It showed low or no activity on 63 other kinases (IC 50 >500 nM), including PLK2 and PLK3 (IC 50 >10,000 nM). Onvansertib is orally bioavailable, offering flexible dosing. Its relatively short 24-hour half-life also allows for flexible dosing and scheduling, which has shown a favorable safety profile in multiple clinical trials. In laboratory studies, onvansertib demonstrated synergistic effects when combined with various cytotoxic agents, including microtubule-targeting agents, topoisomerase 1 inhibitors, antimetabolites, alkylating agents, proteasome inhibitors, kinase inhibitors, PARP inhibitors, BCL-2 inhibitors, and androgen biosynthesis inhibitors.

Cardiff Oncology, Inc. (NASDAQ:CRDF) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 35 items for CRDF at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for CRDF spans 8-K, 10-Q, DEF 14A, 4.

Recent high-impact activity:

  • FDA Grants Fast Track to Onvansertib in First-Line RAS-Mutated Colorectal Cancer
  • Cardiff Q3: Onvansertib PFS Still Not Reached at 21+ Months; Phase 3 Slated for Q1 2027
  • Cardiff Oncology Q3: Cash Falls to $33.8M, Going Concern Reiterated as Phase 3 Looms
  • Cardiff Posts $30.4M Nine-Month Loss; Phase 3 Slips to Q1 2027 Pending Financing
  • Cardiff Oncology CMO Exits as Interim Replacement Takes Over Ahead of Phase 3

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$593K
Net Income
-$45.85M
Diluted EPS
-$0.69
Op. Cash Flow
-$37.92M
Free Cash Flow
-$37.97M
Operating Income
-$48.96M
Cash & Equivalents
$17.47M
Debt / Equity
0.00×
Net Margin
-77.32×
Shares Outstanding
68.31M sh
Source: 10-K · filed 2026-02-24 · accession 0001193125-26-067464

Short Interest & Short Volume

30.82 days to cover

FINRA reported short interest of 12,261,903 shares in CRDF as of the October 30, 2026 settlement, a 1.2% increase from the prior period — about 30.8 days to cover at its recent average daily volume. On November 20, 2026, 42.9% of CRDF volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)12,261,903 shares as of October 30, 2026
Change vs prior period▲ 1.2%
Days to cover30.82 at avg daily volume of 397,871
Daily short volume (FINRA facilities)42.9% of 330,817 shares on November 20, 2026
5-day average short volume54.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for CRDF, detected from its recent SEC filings · based on capital-structure filings through 2026-07-16.

1 recent capital raise

$10.05M Registered Direct Offering · Priced at Premium to Market

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with C →
$0.8358 -1.99% today
52-week range · as of 2026-11-12 $0.7202 – $3.31
Market cap
$66.34M
Volume
521K (0.4× avg)
3-mo avg 1.3M
Live data · 2026-11-22 05:52 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CRDF - Latest Insights

CRDF
Nov 16, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.8328
Real-time Price: $0.8358 info
Change: +$0.0030 (+0.36%) info
Market Cap: $66.344M info
CRDF
Nov 12, 2026, 4:21 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.7276
Real-time Price: $0.8358 info
Change: +$0.1082 (+15%) info
Market Cap: $66.344M info
CRDF
Nov 12, 2026, 4:20 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.7276
Real-time Price: $0.8358 info
Change: +$0.1082 (+15%) info
Market Cap: $66.344M info
CRDF
Nov 12, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.7695
Real-time Price: $0.8358 info
Change: +$0.0663 (+9%) info
Market Cap: $66.344M info
CRDF
Oct 27, 2026, 4:44 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.8988
Real-time Price: $0.8358 info
Change: -$0.063 (-7%) info
Market Cap: $66.344M info
CRDF
Oct 21, 2026, 6:09 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.950
Real-time Price: $0.8358 info
Change: -$0.1142 (-12%) info
Market Cap: $66.344M info
CRDF
Sep 14, 2026, 9:28 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.24
Real-time Price: $0.8358 info
Change: -$0.4023 (-32%) info
Market Cap: $66.344M info
CRDF
Aug 26, 2026, 4:01 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $1.01
Real-time Price: $0.8358 info
Change: -$0.1742 (-17%) info
Market Cap: $66.344M info
CRDF
Aug 11, 2026, 4:36 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.05
Real-time Price: $0.8358 info
Change: -$0.2142 (-20%) info
Market Cap: $66.344M info
CRDF
Aug 11, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.05
Real-time Price: $0.8358 info
Change: -$0.2142 (-20%) info
Market Cap: $66.344M info
CRDF
Aug 11, 2026, 4:01 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.05
Real-time Price: $0.8358 info
Change: -$0.2142 (-20%) info
Market Cap: $66.344M info
CRDF
Jul 16, 2026, 4:03 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $0.916601
Real-time Price: $0.8358 info
Change: -$0.080801 (-9%) info
Market Cap: $66.344M info
CRDF
Jul 16, 2026, 8:43 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.880
Real-time Price: $0.8358 info
Change: -$0.0442 (-5%) info
Market Cap: $66.344M info
CRDF
Jul 16, 2026, 8:38 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.880
Real-time Price: $0.8358 info
Change: -$0.0442 (-5%) info
Market Cap: $66.344M info
CRDF
Jul 16, 2026, 8:36 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $0.8801
Real-time Price: $0.8358 info
Change: -$0.0443 (-5%) info
Market Cap: $66.344M info
CRDF
Jul 15, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.850
Real-time Price: $0.8358 info
Change: -$0.0142 (-2%) info
Market Cap: $66.344M info
CRDF
Jun 11, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.59
Real-time Price: $0.8358 info
Change: -$0.7542 (-47%) info
Market Cap: $66.344M info
CRDF
Jun 03, 2026, 8:33 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.50
Real-time Price: $0.8358 info
Change: -$0.6642 (-44%) info
Market Cap: $66.344M info
CRDF
Jun 03, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.50
Real-time Price: $0.8358 info
Change: -$0.6642 (-44%) info
Market Cap: $66.344M info
CRDF
Jun 02, 2026, 9:06 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.53
Real-time Price: $0.8358 info
Change: -$0.6942 (-45%) info
Market Cap: $66.344M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets